The ESSENCE-Questionnaire for Neurodevelopmental Problems - A Swedish School-Based Validation Study in 11-Year-Old Children.

ESSENCE-Q neurodevelopment school screening

Journal

Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304

Informations de publication

Date de publication:
2022
Historique:
received: 25 05 2022
accepted: 27 07 2022
entrez: 22 9 2022
pubmed: 23 9 2022
medline: 23 9 2022
Statut: epublish

Résumé

To determine the prevalence of parent-rated developmental concern using the ESSENCE-Q (Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations-Questionnaire, 12-items, score range 0-24) and to ascertain the predictive validity and optimal cutoff level of the instrument in a school-based sample of 11-year-old children. In a cross-sectional, school-based study, participants underwent a clinical assessment by a physician and a psychologist, teachers and parents completed the SDQ (Strength and Difficulties Questionnaire), medical health records and national tests were reviewed, and parents independently completed the ESSENCE-Q. In a case-conference outcomes were defined as a) the need for further clinical work-up due to suspected neurodevelopmental problems (NDPs) and b) degree of investigator-rated symptoms/impairment from NDPs on the CGI-S (Clinical Global Impression-Severity instrument, range 1-7, 4-7 defined as clinically symptomatic). Classification and optimal cutoffs of the ESSENCE-Q were determined using ROC (Receiver Operating Characteristic) analysis. Out of 343 eligible children, 223 enrolled, of whom 173 (50% of all eligible) had a parent-rated ESSENCE-Q. At least one of the 12 possible concerns was reported by parents of 36% of participants. Overall, in 101 (57%) participants a work-up was warranted, and 64 (37%) were clinically symptomatic from NDPs. The AUC of the ESSENCE-Q in detecting need for work-up was 0.70 (95% confidence interval [CI] 0.63-0.77), and the AUC in detecting clinically symptomatic participants was 0.82 (95% CI 0.76-0.88). ESSENCE-Q ratings correlated positively with CGI-S scores ( This study of the ESSENCE-Q in 11-year-old children suggests it might be an acceptable instrument for screening of NDPs in children in middle school, optimally in conjunction with other methods.

Identifiants

pubmed: 36133028
doi: 10.2147/NDT.S374930
pii: 374930
pmc: PMC9484576
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2055-2067

Informations de copyright

© 2022 Landgren et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Am J Psychiatry. 2021 Aug 1;178(8):752-760
pubmed: 33900814
J Child Psychol Psychiatry. 2018 Aug;59(8):863-871
pubmed: 29484650
JAMA Psychiatry. 2020 Feb 1;77(2):155-164
pubmed: 31746968
J Child Psychol Psychiatry. 2014 May;55(5):436-45
pubmed: 24274762
Acta Paediatr. 2006 Jun;95(6):664-70
pubmed: 16754546
Seizure. 2019 Oct;71:233-239
pubmed: 31425870
Eur Neuropsychopharmacol. 2013 Dec;23(12):1732-8
pubmed: 23953271
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
J Child Psychol Psychiatry. 2018 Jul;59(7):744-751
pubmed: 29377119
Res Dev Disabil. 2010 Nov-Dec;31(6):1543-51
pubmed: 20634041
Neuropsychiatr Dis Treat. 2018 Aug 23;14:2141-2148
pubmed: 30197517
Eur Child Adolesc Psychiatry. 1999 Jun;8(2):63-70
pubmed: 10435454
Child Adolesc Psychiatry Ment Health. 2013 Dec 10;7(1):40
pubmed: 24325882
J Child Psychol Psychiatry. 2014 Aug;55(8):897-904
pubmed: 24673585
Neuropsychiatr Dis Treat. 2016 Jul 14;12:1739-46
pubmed: 27478377
Int J Methods Psychiatr Res. 2018 Mar;27(1):
pubmed: 29024371
Dev Med Child Neurol. 1996 Oct;38(10):891-906
pubmed: 8870611
Lancet Psychiatry. 2017 Apr;4(4):339-346
pubmed: 27979720
Neuropsychiatr Dis Treat. 2017 May 10;13:1271-1280
pubmed: 28546752
Am J Psychiatry. 2022 Feb;179(2):142-151
pubmed: 34384227
Asian J Psychiatr. 2022 Jul;73:103162
pubmed: 35605519
JAMA Psychiatry. 2020 Sep 1;77(9):936-943
pubmed: 32374377
Acta Paediatr. 2004 Jul;93(7):976-81; discussion 872-3
pubmed: 15303816
Autism Res. 2019 Feb;12(2):176-199
pubmed: 30707000
J Am Acad Child Adolesc Psychiatry. 2022 Aug;61(8):982-996
pubmed: 34958872
Acta Paediatr. 2020 Apr;109(4):764-773
pubmed: 31545530
Eur Child Adolesc Psychiatry. 2003 Aug;12(4):162-71
pubmed: 14505066
Acta Paediatr. 2021 Jul;110(7):2134-2141
pubmed: 33686710

Auteurs

Valdemar Landgren (V)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Psychiatry, Skaraborg Hospital, Skövde, Region Västra Götaland, Sweden.

Leif Svensson (L)

Department of Pediatrics, Skaraborg Hospital, Mariestad, Region Västra Götaland, Sweden.

Rajna Knez (R)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Department of Pediatrics, Skaraborg Hospital, Mariestad, Region Västra Götaland, Sweden.

Michail Theodosiou (M)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Christopher Gillberg (C)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Elisabeth Fernell (E)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Magnus Landgren (M)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Mats Johnson (M)

Gillberg Neuropsychiatry Centre, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Classifications MeSH